{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Xia Q"],"funding":["Shanghai Shen Kang Hospital Development Center"],"pagination":["721"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC8220724"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["21(1)"],"pubmed_abstract":["<h4>Background</h4>Most NSCLCs metastasised out of the lungs at the time of diagnosis and cannot be surgically removed . Cytotoxic chemotherapy drugs have become the main treatment in recent decades, especially in patients with NSCLC without EGFR, ALK, and ROS gene mutations. The prognosis of lung cancer is poor, and the overall 5-year survival rate is only 9-13%. Therefore the treatment of advanced NSCLC remains a significant medical need. Recent studies have shown a significant relationship between the gut-lung axis microecology and malignant tumors. Intestinal probiotics are likely to play a role in inhibiting tumorigenesis through \"intestinal-pulmonary axis microecological regulation\". This study will seek to investigate the efficacy of \"Microbiota modulation of the Gut-Lung Axis\" comb"],"journal":["BMC cancer"],"pubmed_title":["Investigating efficacy of \"microbiota modulation of the gut-lung Axis\" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial."],"pmcid":["PMC8220724"],"funding_grant_id":["SHDC12018119"],"pubmed_authors":["Zhai H","Ren Y","Xia Q","Chen G","Shen C","Gu A","Li M","Xu J","Zheng T","Li Z","Fan L","Jin M","Chen X"],"additional_accession":[]},"is_claimable":false,"name":"Investigating efficacy of \"microbiota modulation of the gut-lung Axis\" combined with chemotherapy in patients with advanced NSCLC: study protocol for a multicenter, prospective, double blind, placebo controlled, randomized trial.","description":"<h4>Background</h4>Most NSCLCs metastasised out of the lungs at the time of diagnosis and cannot be surgically removed . Cytotoxic chemotherapy drugs have become the main treatment in recent decades, especially in patients with NSCLC without EGFR, ALK, and ROS gene mutations. The prognosis of lung cancer is poor, and the overall 5-year survival rate is only 9-13%. Therefore the treatment of advanced NSCLC remains a significant medical need. Recent studies have shown a significant relationship between the gut-lung axis microecology and malignant tumors. Intestinal probiotics are likely to play a role in inhibiting tumorigenesis through \"intestinal-pulmonary axis microecological regulation\". This study will seek to investigate the efficacy of \"Microbiota modulation of the Gut-Lung Axis\" comb","dates":{"release":"2021-01-01T00:00:00Z","publication":"2021 Jun","modification":"2025-04-21T16:38:17.557Z","creation":"2022-02-10T16:21:54.084Z"},"accession":"S-EPMC8220724","cross_references":{"pubmed":["34157996"],"doi":["10.1186/s12885-021-08448-6"]}}